Article info
Letters
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
- Correspondence to Dr Chamaida Plasencia, Rheumatology Department, La Paz University Hospital-Idipaz, Paseo la Castellana 261, Madrid PC 28046, Spain; chamiplasencia{at}hotmail.com
Citation
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
Publication history
- Accepted May 12, 2013
- First published June 5, 2013.
Online issue publication
October 03, 2013
Article Versions
- Previous version (5 June 2013).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions